Le Lézard
Classified in: Covid-19 virus
Subject: Product/Service

ACE Surgical Launches New Business Line Packaging 3D-Printed Nasal Swabs


ACE Surgical Supply Co., a premier dental surgical supply company, has partnered with EnvisionTec, a leading global provider of professional-grade 3D printing, to package and sterilize 3D-printed nasal swabs used for COVID-19 testing as part of a repurposing of the Company's manufacturing capabilities.

As dentistry continues to recover from the pandemic, ACE Surgical is using its excess capacity and expertise to package and sterilize the 3D-printed nasal swabs included in coronavirus test kits. Founded in 1966, ACE Surgical is a manufacturer of dental implants, bone regenerative materials, and a variety of other dental surgical products. Since April, when ACE Surgical launched a new initiative packaging EnvisionTec's 3D-printed nasal swabs, the Company has recalled its entire 15-member production team, reassigned and trained a team to work in the clean room, and created a roadmap for expansion that includes hiring new employees to meet the growing production demand.

Currently, the Company is processing nearly 50,000 testing swabs a day and is building capacity at its Brockton, MA, facility to package 1 million swabs a month. ACE expects to help provide millions of sterile nasal swabs to health care providers and municipalities that are desperately needed to test for the coronavirus. To date, several world-renowned hospitals and state municipalities are among those who have ordered the sterilized nasal swabs packaged by ACE.

"Following the American Dental Association's guidance recommending that U.S dental practitioners suspend seeing patients for elective procedures, we knew that we had to quickly adapt our operations," said Craig Carchidi, Chief Executive Officer of ACE Surgical. "Our entire team has embraced our effort to switch gears and package an essential medical tool that will aid the work of health care providers to implement proper testing and tracing of the COVID-19 virus. As we expand our swab production, we maintain our unwavering commitment to serve the dental-surgical community as a leading global provider of bone regenerative products and compatible dental implant systems."

About ACE Surgical Supply Company

ACE Surgical, a subsidiary of Henry Schein, Inc., is a premier dental surgical supply company based in Brockton, MA and is a manufacturer of dental implants, regenerative materials, and a plethora of other dental products. We pride ourselves in providing an excellent customer experience while focusing on the integrity of our products. For more than 50 years, ACE has become synonymous with quality, innovation, and knowledge. To learn more about the Company and its portfolio of brands, visit www.acesurgical.com.


These press releases may also interest you

at 09:00
Coveo , a leading provider of enterprise AI Search, Recommendations and Generative Experience platforms that enable individualized, connected, and trusted digital experiences at scale with unified relevance, today announced two new GenAI business...

at 08:49
Cove Capital Investments reviews and analyzes nearly every type of asset class available for Delaware Statutory Trust investors.  This list of potential DST property asset classes includes government leased buildings, self-storage facilities,...

at 08:40
The "United States Self-Monitoring Blood Glucose Devices Market Growth, Share, Size, Trends, Analysis and Forecast (2024 - 2032)" report has been added to ResearchAndMarkets.com's offering. The U.S. Self-Monitoring Blood Glucose Devices market size...

at 08:35
Arch Insurance North America (Arch), a provider of specialized insurance and risk management solutions, today unveiled its latest products available through the Arch APEX? digital platform. Participant Accident coverage is now available for child...

at 08:35
Gilead Sciences, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application (sNDA) for Vemlidy® (tenofovir alafenamide) 25 mg tablets as a once-daily treatment for chronic hepatitis B...

at 08:35
Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today reported financial...



News published on and distributed by: